toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
Details
   print
  Record Links
Author Chawes, B.L.; Govoni, M.; Kreiner-Moller, E.; Vissing, N.H.; Poorisrisak, P.; Mortensen, L.; Nilsson, E.; Bisgaard, A.; Dossing, A.; Deleuran, M.; Skytt, N.L.; Samandari, N.; Piccinno, A.; Sergio, F.; Ciurlia, G.; Poli, G.; Acerbi, D.; Singh, D.; Bisgaard, H. url  doi
openurl 
  Title Systemic exposure to inhaled beclometasone/formoterol DPI is age and body size dependent Type Journal Article
  Year (down) 2014 Publication Respiratory Medicine Abbreviated Journal Respir Med  
  Volume 108 Issue 8 Pages 1108-1116  
  Keywords Administration, Inhalation; Adolescent; Adult; Age Factors; Aged; Analysis of Variance; Anti-Asthmatic Agents/administration & dosage/*pharmacokinetics; Asthma/*drug therapy/physiopathology; Beclomethasone/administration & dosage/*pharmacokinetics; Body Size/physiology; Child; Cross-Over Studies; Ethanolamines/administration & dosage/*pharmacokinetics; Forced Expiratory Volume/drug effects; Formoterol Fumarate; Half-Life; Humans; Metered Dose Inhalers; Middle Aged; Young Adult; Adolescents; Asthma; Beclometasone-dipropionate; Children; Dpi; Formoterol  
  Abstract AIM: Prescription of inhaled corticosteroids to children with asthma is recommended at half the nominal dose of adults in order to reduce the risk of systemic side effects. However, there is a lack of pharmacokinetic trials supporting such dose reduction regimens. Therefore, we aimed to compare the systemic exposure to the active ingredients of a fixed dose combination of beclometasone-dipropionate (BDP) and formoterol after dry powder inhaler (DPI) administration in children, adolescents and adults. METHODS: The pharmacokinetic profiles of formoterol and beclometasone-17-monopropionate (B17MP; active metabolite of BDP) were evaluated over 8 h from two independent studies comprising children (6-11yrs, n = 27), adolescents (12-17 yrs, n = 28) and adults (>/=18 yrs, n = 30) receiving a single, fixed dose of BDP/formoterol (children: 200 mug/24 mug, adolescents and adults: 400 mug/24 mug) via DPI. RESULTS: The systemic exposure (AUC) for children versus adults was almost doubled for formoterol and similar for B17MP despite the halved BDP dose administered in children. In adolescents the AUC for formoterol and B17MP were approximately one third higher than in adults for both compounds. Upon normalization for the BDP/formoterol dose in the three populations the AUC and peak concentration (C(max)) correlated inversely with age and body surface area of the patients (r </= -0.53; p < 0.0001). CONCLUSION: The systemic exposure to the active ingredients of BDP/formoterol administered as DPI correlates inversely with age and body size suggesting that dry powder dosage regimens should be adjusted for age and body size to avoid high systemic drug levels in children.  
  Address Copenhagen Prospective Studies on Asthma in Childhood, Health Sciences, University of Copenhagen & Danish Pediatric Asthma Center, Copenhagen University Hospital, Gentofte, Denmark. Electronic address: bisgaard@copsac.com  
  Corporate Author Thesis  
  Impact Factor 03,086 First Author Chawes, B.L. Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Senior Author Bisgaard, H.  
  ISSN 0954-6111 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:24993817 Approved no  
  Call Number Serial 49  
Permanent link to this record
Select All    Deselect All
 |   | 
Details
   print

Save Citations:
Export Records: